Search results
Sep 10, 2024 · Remdesivir and nirmatrelvir/ritonavir (antiviral agents), baricitinib (an immunomodulatory drug), and 2 mRNA vaccines have gained full FDA approval for prevention and treatment of COVID-19...
Sep 10, 2024 · See the article Coronavirus Disease 2019 (COVID-19) in Emergency Medicine. The Medscape article Acute Respiratory Distress Syndrome (ARDS) includes discussions of fluid management,...
Feb 29, 2024 · Searching for effective therapies for COVID-19 infection is a complex process. Guidelines for COVID-19 have been published and continue to be revised as evidence emerges. [7, 8] The Milken...
- Hypersensitivity
- Clinical Worsening After Administration
- Severe Covid-19
- Viral Variants
- Drug Interaction Overview
Serious hypersensitivity reaction, including anaphylaxis, may occurHypersensitivity reactions occurring more >24 hr after the infusion have also been reported with SARS-CoV-2 monoclonal antibodies under EUAIf signs and symptoms occur, immediately discontinue IV infusion, and initiate appropriate medications and/or supportive careInfusion-related reactions reported, including fever, difficulty breathing, reduced oxygen saturation, chills, fatigue, arrhythmia (eg, atrial fibrillation, sinus tachycardia, bradycardia), chest p...Clinical worsening of COVID-19 after administration reported; signs or symptoms may include fever, hypoxia or increased respiratory difficulty, arrhythmia (eg, atrial fibrillation, sinus tachycardi...Some of these events required hospitalizationUnknown if these events were related to the monoclonal antibodies or were due to progression of COVID-19Treatment benefit not observed in patients hospitalized with COVID-19Monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high-flow oxygen or mechanical ventilationTherefore, use is not authorized for use in patientsCirculating SARS-CoV-2 viral variants may be associated with resistance to monoclonal antibodiesPrescribing clinicians should consider prevalence of etesevimab resistant variants in their areaHealthcare providers should review antiviral resistance information provided by state and local health departmentsVariant proportions circulating in the United States can be monitored at the CDC websiteNot renally excreted or metabolized by CYP450 enzymesInteractions with concomitant renally excreted drugs or drugs that are CYP450 substrates, inducers, or inhibitors are unlikelyJul 15, 2020 · Worldwide, scientists have launched over 1000 clinical trials of drugs for the treatment and prevention of SARS-CoV-2 since the start of January. Here's our very quick summary.
Medscape's Pill Identifier helps you to ID generic and brand name prescription drugs, OTCs, and supplements. Search from over 10,000 tablets and capsules by imprint, color, shape, form, and...
Mar 23, 2021 · This guideline covers managing COVID-19 in babies, children, young people and adults in community and hospital settings. It includes recommendations on communication, assessment, therapeutics for COVID-19, non-invasive respiratory support, preventing and managing acute complications, and identifying and managing co-infections.
